Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
4(40%)
Results Posted
100%(5 trials)

Phase Distribution

Ph phase_2
2
20%
Ph phase_4
1
10%
Ph phase_3
6
60%
Ph phase_1
1
10%

Phase Distribution

1

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
6(60.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(5)

Detailed Status

Completed5
Recruiting3
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 22 (20.0%)
Phase 36 (60.0%)
Phase 41 (10.0%)

Trials by Status

active_not_recruiting110%
not_yet_recruiting110%
completed550%
recruiting330%

Recent Activity

4 active trials
Showing 5 of 10
recruitingphase_3

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

NCT07653100
recruitingphase_3

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

NCT06866405
not_yet_recruitingphase_4

Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF

NCT07693166
recruitingphase_3

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

NCT07543380
active_not_recruitingphase_3

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

NCT05035212
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07653100Phase 3

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

Recruiting
NCT06866405Phase 3

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

Recruiting
NCT07693166Phase 4

Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF

Not Yet Recruiting
NCT07543380Phase 3

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

Recruiting
NCT05035212Phase 3

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

Active Not Recruiting
NCT05842967Phase 3

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

Completed
NCT04424316Phase 3

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Completed
NCT05886777Phase 2

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Completed
NCT05788237Phase 1

A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults

Completed
NCT04785612Phase 2

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10